Company Performance: Strong revenue growth, profitability, and successful clinical trial outcomes typically drive the stock price higher. Conversely, poor financial results or trial failures can lead to price declines.

Industry Trends: Positive developments in the biotechnology sector, such as new drug approvals or advancements in cancer research, can boost investor confidence and increase demand for BIOSK.AT shares.

Regulatory Environment: Changes in regulations regarding drug approvals, pricing, or healthcare policies can significantly impact the company's future prospects and consequently affect the stock price.

Market Sentiment: Overall investor confidence and risk appetite play a crucial role. A bullish market environment tends to support higher stock prices, while a bearish market can depress them.

Competition: The emergence of new competitors or the success of competing products can erode BIOSK.AT's market share and negatively affect its stock price.

Economic Conditions: Broader economic factors such as interest rates, inflation, and economic growth can influence investor sentiment and affect the valuation of BIOSK.AT.

News & Events: Announcements related to partnerships, acquisitions, or significant scientific breakthroughs can trigger substantial price movements in BIOSK.AT stock.

Specific Drug Pipeline: Positive or negative results from clinical trials for key drugs in BIOSK.AT's pipeline will significantly move the stock.

Management Team: Changes in the leadership team or perceptions of the management's competence can influence investor confidence.